QGEN vs. TECH: Qiagen vs. Bio-Techne Stock Comparison

November 11, 2026

How do Qiagen (QGEN) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Qiagen (QGEN) and Bio-Techne (TECH) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Qiagen (QGEN) and Bio-Techne (TECH)
Profile Item	QGEN	TECH
Name	Qiagen N.V.	Bio-Techne Corp.
Country/Region	Netherlands	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
GICS Sub-Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
Market Capitalization	10.39 billion USD	11.43 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	June 28, 1996	February 9, 1989
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

QGEN

TECH

GSPC

Qiagen (QGEN) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Qiagen (QGEN) and Bio-Techne (TECH). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Qiagen (QGEN) and Bio-Techne (TECH). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Qiagen (QGEN) and Bio-Techne (TECH)
Metric	QGEN	TECH
Total Return (1Y)	17.09%	27.56%
Total Return (3Y, Annualized)	10.44%	9.11%
Total Return (5Y, Annualized)	-0.72%	-9.91%

Risk Profile

Drawdown History

QGEN

TECH

GSPC

Qiagen (QGEN) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Qiagen (QGEN) and Bio-Techne (TECH). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Qiagen (QGEN) and Bio-Techne (TECH)
Metric	QGEN	TECH
Volatility (1Y, Annualized)	35.52%	43.08%
Beta (5Y)	0.56	1.26
Max Drawdown (5Y)	-41.97%	-65.87%
Avg. Volume (3M)	3.68M	2.81M

Risk-Adjusted Performance

Risk-Return Positioning

QGEN and TECH are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Qiagen (QGEN) and Bio-Techne (TECH)
Metric	QGEN	TECH
Sharpe Ratio (1Y)	0.36	0.54
Sortino Ratio (1Y)	0.60	0.82

Profitability

ROE (TTM)

Both Qiagen (QGEN) at 10.81% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.81%

Max: 109.18%
QGEN: 10.81%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.33%

Max: 109.18%
TECH: 8.33%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Qiagen (QGEN) at 18.20% keeps the most of each sales dollar — above its industry’s net margin range — and Bio-Techne (TECH) at 14.00% also retains a top-quartile share.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.20%

QGEN: 18.20%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.00%

Max: 18.05%
TECH: 14.00%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Qiagen (QGEN) at 27.75% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.75%

Max: 83.12%
QGEN: 27.75%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.21%

Max: 83.12%
Q3: 14.77%
TECH: 12.21%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Qiagen (QGEN) and Bio-Techne (TECH)
Metric	QGEN	TECH
ROE (TTM)	10.81%	8.33%
ROA (TTM)	5.68%	6.38%
Net Margin (TTM)	18.20%	14.00%
Operating Margin (TTM)	27.75%	12.21%
Gross Margin (TTM)	67.06%	66.23%

Growth

Revenue Growth

Both Qiagen (QGEN) at 5.65% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both companies show strong earnings momentum, but Qiagen (QGEN) at 409.76% is the standout with EPS growth above its industry range; Bio-Techne (TECH) at 152.17% also sits in the top quartile.

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Qiagen (QGEN) and Bio-Techne (TECH)
Metric	QGEN	TECH
Revenue Growth (YoY)	5.65%	-0.38%
Revenue Growth (3Y CAGR)	-0.81%	2.25%
EPS Growth (YoY)	409.76%	152.17%
EPS Growth (3Y CAGR)	-0.19%	-12.97%

Financial Strength

Current Ratio (MRQ)

Qiagen (QGEN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Bio-Techne (TECH) at 2.28 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TECH.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max: 25.13
Q3: 12.13
Median: 5.52
QGEN: 2.63
Q1: 2.47
Min: 0.10

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.28

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TECH: 2.28
Min: 0.10

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Qiagen (QGEN) at 0.47 and Bio-Techne (TECH) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.47

Max: 1.42
Q3: 0.65
QGEN: 0.47
Median: 0.15
Q1: 0.02
Min: 0.00

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.13

Max: 1.42
Q3: 0.65
Median: 0.15
TECH: 0.13
Q1: 0.02
Min: 0.00

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Qiagen (QGEN) and Bio-Techne (TECH)
Metric	QGEN	TECH
Current Ratio (MRQ)	2.63	2.28
Debt / Equity (MRQ)	0.47	0.13
Net Debt / EBITDA	1.08	-0.20

Dividends

Dividend Yield (TTM)

Both Qiagen (QGEN) at 0.71% and Bio-Techne (TECH) at 0.44% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71%

QGEN: 0.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.44%

TECH: 0.44%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Qiagen (QGEN) at 18.21% and Bio-Techne (TECH) at 27.59% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.21%

QGEN: 18.21%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.59%

TECH: 27.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Qiagen (QGEN) and Bio-Techne (TECH)
Metric	QGEN	TECH
Dividend Yield (TTM)	0.71%	0.44%
Dividend Payout Ratio (TTM)	18.21%	27.59%

Valuation

P/E Ratio (TTM)

Qiagen (QGEN) at 27.21 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.21

Max: 85.34
Q3: 43.46
QGEN: 27.21
Median: 26.69
Q1: 13.30
Min: 0.07

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

62.74

Max: 85.34
TECH: 62.74
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Qiagen (QGEN) at 4.91 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.91

Max: 58.18
Q3: 25.77
Median: 7.30
QGEN: 4.91
Q1: 3.01
Min: 0.01

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.31

Max: 58.18
Q3: 25.77
TECH: 9.31
Median: 7.30
Q1: 3.01
Min: 0.01

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Qiagen (QGEN) at 2.99 and Bio-Techne (TECH) at 5.28 are valued close to their industries’ norm against book — neither stands out from peers.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.99

Max: 13.53
Q3: 6.54
Median: 3.25
QGEN: 2.99
Q1: 1.69
Min: -5.59

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.28

Max: 13.53
Q3: 6.54
TECH: 5.28
Median: 3.25
Q1: 1.69
Min: -5.59

Qiagen (QGEN) vs. Bio-Techne (TECH): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Qiagen (QGEN) and Bio-Techne (TECH)
Metric	QGEN	TECH
P/E Ratio (TTM)	27.21	62.74
P/S Ratio (TTM)	4.91	9.31
P/B Ratio (MRQ)	2.99	5.28
Free Cash Flow Yield (TTM)	3.62%	2.39%